肺血管疾病的新分类-英文课件演示文稿.ppt

New Classification of Pulmonary Vascular Disease;“Inclusive” New Classification of Pulmonary Hypertension;;Pulmonary Vasuclar Disease:Talk Outline;Rx: First Treat the Underlying Disease (1);Treatment of Pulmonary Vascular Disease;Suspected Pulmonary Hypertension;Work-Up of Pulmonary Hypertension;Right Heart Catheterization;Pathogenesis of Pulmonary Vascular Lesion;The Vasodilator Trial;Vasodilator Management:Response to Therapy;The Paradox of Epoprostenol Therapy ;Choosing a Calcium Channel Blocker;Right Heart Catheterization and Vasodilator Trial;Epoprostenol Side Effects;Continuous Intravenous Epoprostenol;Adjunct Therapy in Pulmonary Vascular Disease;Treatment in Pulmonary Vascular Disease;Natural History of the Response to Epoprostenol;Intravenous Vasodilators in Pulmonary Hypertension;Vasodilator Management:Response to Therapy;Monitoring the Effects of Chronic Therapy;Right Heart Catheterization and Vasodilator Trial;Transplantation for Pulmonary Hypertension: Role of Epoprostenol;Portopulmonary Hypertension: Prostacyclin Therapy;Eisenmengers:Prostacyclin Therapy;Epoprostenol;Epoprostenol;The Influence of Epoprostenol on the Timing and Outcome of Transplantation;Medical Management of Pulmonary Vascular Disease: Summary